2024-03-29T08:27:36Zhttp://repisalud.isciii.es/oai/requestoai:repisalud.isciii.es:20.500.12105/112912023-11-03T12:25:08Zcom_20.500.12105_15322com_20.500.12105_2051com_20.500.12105_2123com_20.500.12105_2052com_20.500.12105_2060col_20.500.12105_16961col_20.500.12105_2124col_20.500.12105_2061
Repisalud
author
Díez-Fuertes, Francisco
author
Iglesias-Caballero, Maria
author
García-Pérez, Javier
author
Monzon-Fernandez, Sara
author
Jimenez Sancho, Maria Pilar
author
Varona Fernandez, Sarai
author
Cuesta de la Plaza, Isabel
author
Zaballos, Ángel
author
Jimenez, Mercedes
author
Checa, Laura
author
Pozo Sanchez, Francisco
author
Perez-Olmeda, Mayte
author
Thomson, Michael M
author
Alcamí, José
author
Casas Flecha, Inmaculada
funder
Red de Investigación Cooperativa en Investigación en Sida (España)
funder
Instituto de Salud Carlos III
funder
Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
2020-11-04T12:48:55Z
2020-11-04T12:48:55Z
2021-01
J Virol. 2021 Jan 13;95(3):e01583-20.
0022-538X
http://hdl.handle.net/20.500.12105/11291
33127745
10.1128/JVI.01583-20
1098-5514
Journal of virology
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) whole-genome analysis has identified five large clades worldwide which emerged in 2019(19A and 19B) and in 2020 (20A, 20B, and 20C). This study aimed to analyze the dif-fusion of SARS-CoV-2 in Spain using maximum-likelihood phylogenetic and Bayesianphylodynamic analyses. The most recent common ancestor (MRCA) of the SARS-CoV-2 pandemic was estimated to have emerged in Wuhan, China, around 24 No-vember 2019. Phylogenetic analyses of the first 12,511 SARS-CoV-2 whole-genomesequences obtained worldwide, including 290 from 11 different regions of Spain, re-vealed 62 independent introductions of the virus in the country. Most sequencesfrom Spain were distributed in clades characterized by a D614G substitution in the Sgene (20A, 20B, and 20C) and an L84S substitution in ORF8 (19B) with 163 and 118sequences, respectively, with the remaining sequences branching in 19A. A total of110 (38%) sequences from Spain grouped in four different monophyletic clusters ofclade 20A (20A-Sp1 and 20A-Sp2) and 19B clade (19B-Sp1 and 19B-Sp2) along withsequences from 29 countries worldwide. The MRCAs of clusters 19A-Sp1, 20A-Sp1,19A-Sp2, and 20A-Sp2 were estimated to have occurred in Spain around 21 and 29January and 6 and 17 February 2020, respectively. The prevalence of clade 19B inSpain (40%) was by far higher than in any other European country during the firstweeks of the epidemic, probably as a result of a founder effect. However, this vari-ant was replaced by G614-bearing viruses in April.In vitroassays showed an en-hanced infectivity of pseudotyped virions displaying the G614 substitution comparedwith those having D614, suggesting a fitness advantage of D614G.
eng
COVID-19
Europe
SARS-CoV
Spain
Phylodynamics
A Founder Effect Led Early Sars-Cov-2 Transmission In Spain
journal article
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
URL
https://repisalud.isciii.es/bitstream/20.500.12105/11291/10/FounderEffectLedEarlySARS-CoV-2_2021.pdf
File
MD5
b2224b3c3030f038b4a69764f3d3e7ac
4401296
application/pdf
FounderEffectLedEarlySARS-CoV-2_2021.pdf
URL
https://repisalud.isciii.es/bitstream/20.500.12105/11291/6/AFounderEffectLed_2020.pdf.txt
File
MD5
b47fdd85fdabc03d03a46f700ee8b5fe
64264
text/plain
AFounderEffectLed_2020.pdf.txt
URL
https://repisalud.isciii.es/bitstream/20.500.12105/11291/9/AFounderEffectLedEarlySARS-CoV-2_2021.pdf.txt
File
MD5
26123005da887254fe705a0fe026284f
64708
text/plain
AFounderEffectLedEarlySARS-CoV-2_2021.pdf.txt
URL
https://repisalud.isciii.es/bitstream/20.500.12105/11291/11/FounderEffectLedEarlySARS-CoV-2_2021.pdf.txt
File
MD5
ca4d23ec63823bbd7ba40ce23c52aed2
64693
text/plain
FounderEffectLedEarlySARS-CoV-2_2021.pdf.txt